Ventrus Biosciences has selected inVentiv Clinical Solutions to manage its Phase III trial with Iferanserin in development for the treatment of hemorrhoids. Ventrus has selected Almac Group to provide electronic patient-reported outcomes solutions.

Ventrus plans to initiate its first Phase III trial in 2011 and expects data in 1Q12. The study will enroll 400 patients who will be randomized to receive placebo or Iferanserin. The primary endpoint is cessation of bleeding.

Russell Ellison, chief executive officer of Ventrus, said, “During our selection process, we were looking for strategic partners who have a proven track record with gastrointestinal studies and track record of success. inVentiv and Almac rose above the other research organizations and we are delighted to be working with them.”


Click here to learn more about Almac Group